Skip to main content

ORIGINAL RESEARCH article

Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 11 - 2024 | doi: 10.3389/fmolb.2024.1513919
This article is part of the Research Topic Cancer Biomarkers: Molecular Insights into Diagnosis, Prognosis, and Risk Prediction View all 4 articles

CircMIB1 inhibits glioma development and progression through a competing endogenous RNA interaction network

Provisionally accepted
Simin Chen Simin Chen 1Longping Li Longping Li 1Wei Xu Wei Xu 1Nanjiao Xie Nanjiao Xie 1Huiting Xu Huiting Xu 1Yongjun Zhou Yongjun Zhou 1Ying Zou Ying Zou 1Yi Kai Yi Kai 1,2Yi Liu Yi Liu 2*
  • 1 Yiyang Central Hospital, Yiyang, China
  • 2 Sichuan University, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    The critical role of circular RNAs (circRNAs) as non-coding RNAs in glioma has been extensively investigated. In this study, firstly, a novel circRNA molecule termed circRNA-mind bomb homolog 1 (circMIB1) was identified and validated by RNA sequencing and quantitative real-time polymerase chain reaction. The expression of circMIB1 was significantly downregulated in glioma cells and tissues, and was closely associated with the tumor grade and survival prognosis of patients with glioma. Hence, it may be useful as a biomarker for glioma. Secondly, it was predicted that circMIB1 binds to hsa-miR-1290 based on bioinformatics analysis, which was significantly upregulated in glioma cells and tissues, and correlated with the tumor grade and overall survival of patients. Thirdly, through a series of bioinformatics analyses identified six genes downstream of hsa-miR-1290 that were significantly associated with glioma expression and prognosis, these genes are associated with cell cycle, cell necrosis and cell circadian rhythms. Taken together, the results of this study suggest that circMIB1 may play a role in inhibiting glioma development through the hsa-miR-1290 competitive endogenous RNA interaction network. These findings provide new ideas and directions for the diagnosis and treatment of glioma.

    Keywords: CircMIB1, Glioma, MiR-1290, ceRNA, prognostic, biomarker

    Received: 19 Oct 2024; Accepted: 13 Nov 2024.

    Copyright: © 2024 Chen, Li, Xu, Xie, Xu, Zhou, Zou, Kai and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yi Liu, Sichuan University, Chengdu, 610065, Sichuan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.